## David Krug

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1826302/publications.pdf

Version: 2024-02-01

96	1,648	21	34
papers	citations	h-index	g-index
130	130	130	1759
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Heart toxicity from breast cancer radiotherapy. Strahlentherapie Und Onkologie, 2019, 195, 1-12.	1.0	142
2	Heart-sparing radiotherapy techniques in breast cancer patients: aÂrecommendation of the breast cancer expert panel of the German society of radiation oncology (DEGRO). Strahlentherapie Und Onkologie, 2019, 195, 861-871.	1.0	82
3	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care, 2019, 14, 224-245.	0.8	72
4	DEGRO practical guideline for partial-breast irradiation. Strahlentherapie Und Onkologie, 2020, 196, 749-763.	1.0	66
5	DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrences. Strahlentherapie Und Onkologie, 2016, 192, 199-208.	1.0	64
6	Influence of human papillomavirus and p16INK4a on treatment outcome of patients with anal cancer. Radiotherapy and Oncology, 2014, 113, 331-336.	0.3	54
7	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care, 2021, 16, 214-227.	0.8	51
8	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Breast Care, 2022, 17, 403-420.	0.8	43
9	Stereotactic body radiotherapy for ventricular tachycardia (cardiac radiosurgery). Strahlentherapie Und Onkologie, 2020, 196, 23-30.	1.0	41
10	Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward. Strahlentherapie Und Onkologie, 2021, 197, 269-280.	1.0	41
11	Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA). Clinical Research in Cardiology, 2020, 109, 1319-1332.	1.5	40
12	Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial). International Journal of Radiation Oncology Biology Physics, 2021, 109, 1311-1324.	0.4	37
13	Current controversies in radiotherapy for breast cancer. Radiation Oncology, 2017, 12, 25.	1.2	33
14	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care, 2019, 14, 247-255.	0.8	32
15	Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature. Critical Reviews in Oncology/Hematology, 2019, 141, 102-111.	2.0	31
16	Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis. Radiation Oncology, 2014, 9, 113.	1.2	30
17	Quality of training in radiation oncology in Germany: where do we stand?. Strahlentherapie Und Onkologie, 2018, 194, 293-302.	1.0	30
18	Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stageÂllI non-small cell lung cancer. Strahlentherapie Und Onkologie, 2018, 194, 79-90.	1.0	30

#	Article	IF	CITATIONS
19	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Annals of Surgical Oncology, 2019, 26, 3892-3901.	0.7	29
20	Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer. Strahlentherapie Und Onkologie, 2018, 194, 607-618.	1.0	28
21	Interdisciplinary Clinical Target Volume Generation for Cardiac Radioablation: Multicenter Benchmarking for the RAdiosurgery for VENtricular TAchycardia (RAVENTA) Trial. International Journal of Radiation Oncology Biology Physics, 2021, 110, 745-756.	0.4	28
22	Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. European Journal of Cancer, 2020, 130, 92-101.	1.3	26
23	Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia. Heart Rhythm, 2021, 18, 2137-2145.	0.3	25
24	Quality of teaching radiation oncology in Germany—where do we stand?. Strahlentherapie Und Onkologie, 2020, 196, 699-704.	1.0	21
25	Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials Journal of Clinical Oncology, 2015, 33, 1008-1008.	0.8	21
26	Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. Journal of Radiation Research, 2015, 56, 742-749.	0.8	20
27	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care, 2021, 16, 228-235.	0.8	20
28	Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 683-693.	0.4	20
29	Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. Tumori, 2019, 105, 174-180.	0.6	19
30	Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of aAprospective trial. Strahlentherapie Und Onkologie, 2021, 197, 48-55.	1.0	18
31	AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Und Frauenheilkunde, 2021, 81, 1112-1120.	0.8	17
32	Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. Journal of Clinical Oncology, 2019, 37, 1490-1498.	0.8	16
33	RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clinical and Translational Radiation Oncology, 2020, 23, 43-49.	0.9	16
34	Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation. Journal of Contemporary Brachytherapy, 2019, 11, 312-319.	0.4	15
35	Neoadjuvant chemotherapy for breast cancer—background for the indication of locoregional treatment. Strahlentherapie Und Onkologie, 2018, 194, 797-805.	1.0	14
36	Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clinical and Translational Radiation Oncology, 2021, 28, 90-96.	0.9	14

#	Article	IF	CITATIONS
37	Whole brain helical Tomotherapy with integrated boost for brain metastases in patients with malignant melanoma–a randomized trial. Radiation Oncology, 2013, 8, 234.	1.2	13
38	Prospective phase-II-study evaluating postoperative radiotherapy of cervical and endometrial cancer patients using protons – the APROVE-trial. Radiation Oncology, 2017, 12, 188.	1,2	13
39	The impact of vaginal dilator use on vaginal stenosis and sexual quality of life in women treated with adjuvant radiotherapy for endometrial cancer. Strahlentherapie Und Onkologie, 2019, 195, 902-912.	1.0	13
40	Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. Radiation Oncology, 2020, 15, 235.	1.2	13
41	Minor cartilage collagens type IX and XI are expressed during embryonic stem cell-derived in vitro chondrogenesis. Annals of Anatomy, 2013, 195, 88-97.	1.0	12
42	Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial. Strahlentherapie Und Onkologie, 2021, 197, 802-811.	1.0	12
43	Comparing Local and Systemic Control between Partial- and Whole-Breast Radiotherapy in Low-Risk Breast Cancer—A Meta-Analysis of Randomized Trials. Cancers, 2021, 13, 2967.	1.7	12
44	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers, 2022, 14, 521.	1.7	12
45	No Difference in Overall Survival and Non-Breast Cancer Deaths after Partial Breast Radiotherapy Compared to Whole Breast Radiotherapy—A Meta-Analysis of Randomized Trials. Cancers, 2020, 12, 2309.	1.7	11
46	Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis. Strahlentherapie Und Onkologie, 2021, 197, 812-819.	1.0	11
47	Oligometastasis in breast cancer—current status and treatment options from aÂradiation oncology perspective. Strahlentherapie Und Onkologie, 2022, 198, 601-611.	1.0	11
48	Radiotherapy of Ductal Carcinoma In Situ. Breast Care, 2015, 10, 259-264.	0.8	10
49	Radiotherapy after skin-sparing mastectomy with immediate breast reconstruction in intermediate-risk breast cancer. Strahlentherapie Und Onkologie, 2019, 195, 949-963.	1.0	10
50	Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review. Breast Care, 2020, 15, 118-127.	0.8	10
51	Situation of young radiation oncologists, medical physicists and radiation biologists in German-speaking countries. Strahlentherapie Und Onkologie, 2016, 192, 507-515.	1.0	9
52	Neoadjuvant chemotherapy for early breast cancer. Lancet Oncology, The, 2018, 19, e129.	5.1	9
53	Acute Toxicity and Early Oncological Outcomes After Intraoperative Electron Radiotherapy (IOERT) as Boost Followed by Whole Breast Irradiation in 157 Early Stage Breast Cancer Patients—First Clinical Results From a Single Center. Frontiers in Oncology, 2019, 9, 384.	1.3	9
54	Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancerâ€"results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. Strahlentherapie Und Onkologie, 2021, 197, 385-395.	1.0	9

#	Article	IF	CITATIONS
55	Peer review analysis in the field of radiation oncology: results from aÂweb-based survey of the Young DEGRO working group. Strahlentherapie Und Onkologie, 2021, 197, 667-673.	1.0	9
56	Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations. Strahlentherapie Und Onkologie, 2022, 198, 1-11.	1.0	9
57	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. Breast Care, 2022, 17, 421-429.	0.8	9
58	Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients—sequentially, or better simultaneously?. Strahlentherapie Und Onkologie, 2021, 197, 1-7.	1.0	8
59	Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases: An outcome analysis of a pooled multi-platform patient cohort. Radiotherapy and Oncology, 2021, 158, 230-236.	0.3	8
60	Post-Neoadjuvant Treatment Strategies in Breast Cancer. Cancers, 2022, 14, 1246.	1.7	8
61	<p>Whole-brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma – final results of the BRAIN-RT trial</p> . Cancer Management and Research, 2019, Volume 11, 4669-4676.	0.9	7
62	Adjuvant Radiotherapy for Breast Cancer: More than Meets the Eye. Breast Care, 2020, 15, 109-111.	0.8	7
63	Innovative radiation oncology Together– Precise,ÂPersonalized,ÂHuman. Strahlentherapie Und Onkologie, 2021, 197, 1043-1048.	1.0	7
64	Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial. Radiotherapy and Oncology, 2021, 163, 165-176.	0.3	7
65	Radiotherapy and Its Intersections with Surgery in the Management of Localized Gynecological Malignancies: A Comprehensive Overview for Clinicians. Journal of Clinical Medicine, 2021, 10, 93.	1.0	7
66	Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials. Breast, 2022, 64, 136-142.	0.9	7
67	Intrafractional dose variation and beam configuration in carbon ion radiotherapy for esophageal cancer. Radiation Oncology, 2016, 11, 150.	1.2	5
68	Patient Reported Experience with Treatment Modalities and Safety of Adjuvant Breast Radiotherapy - First Results of the Randomized HYPOSIB – Study. International Journal of Radiation Oncology Biology Physics, 2020, 108, S13.	0.4	5
69	Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419). Radiation Oncology, 2020, 15, 134.	1.2	5
70	Long-Term Results of the TARGIT-A Trial: More Questions than Answers. Breast Care, 2022, 17, 81-84.	0.8	5
71	Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Und Frauenheilkunde, 2021, 81, 637-653.	0.8	5
72	Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2021, 81, 654-665.	0.8	4

#	Article	IF	Citations
73	Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy. Breast Care, 2018, 13, 440-446.	0.8	3
74	Challenges in Radiotherapy. Breast Care, 2019, 14, 152-158.	0.8	3
75	Tumor-dose-rate variations during robotic radiosurgery of oligo and multiple brain metastases. Strahlentherapie Und Onkologie, 2020, 197, 581-591.	1.0	3
76	Incidental irradiation of the regional lymph nodes during deep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a dosimetric analysis. BMC Cancer, 2022, 22, .	1.1	3
77	Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials. Strahlentherapie Und Onkologie, 2019, 195, 306-307.	1.0	2
78	Patient-Reported Outcomes Assessing the Impact of Palliative Radiotherapy on Quality of Life and Symptom Burden in Head and Neck Cancer Patients: A Systematic Review. Frontiers in Oncology, 2021, 11, 683042.	1.3	2
79	Expert Discussion: Hypofractionated Radiation Therapy – Standard for All Indications?. Breast Care, 0,	0.8	2
80	Editorial commentary: Stereotactic ablative radiotherapy for cardiac arrhythmia – A rising STAR?. Trends in Cardiovascular Medicine, 2022, 32, 297-298.	2.3	1
81	Randomized surgical multicenter trial to evaluate the usefulness of lymphoscintigraphy (LSG) prior to sentinel node biopsy (SLNB) in early breast cancer: SenSzi (GBG80) trial Journal of Clinical Oncology, 2017, 35, 555-555.	0.8	1
82	Radiotherapy for Ductal Cancer In Situ (DCIS) of the Breast. , 2018, , 1-17.		0
83	OC-0329: Predictive value of GTV in radiotherapy of NSCLC - early results of the NCT03055715 trial. Radiotherapy and Oncology, 2018, 127, S175.	0.3	0
84	EP-1692: Quality of Radiation Oncology Training in Germany: Results from the 2017 survey of the young DEGRO. Radiotherapy and Oncology, 2018, 127, S908-S909.	0.3	0
85	Reply to E. Hindié and A.K. Goel et al. Journal of Clinical Oncology, 2019, 37, 2705-2707.	0.8	0
86	Beyond the scalpel – mortality after liver surgery in patients with liver metastases – time to rethink the indications. British Journal of Surgery, 2019, 107, 149-149.	0.1	0
87	Post-Neoadjuvant Therapy. Breast Care, 2019, 14, 409-413.	0.8	0
88	First 2-Year Results of the Multicenter, Randomized IMRT-MC2 Trial (MINT): Intensity-Modulated Radiotherapy with Simultaneous Integrated Boost versus 3-D-Conformal Radiotherapy with Consecutive Boost for Breast Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2020, 108, S10.	0.4	0
89	Reply to: The challenge of cardiac dose constraint adaptation to hypofractionated breast radiotherapy in clinical practice. Strahlentherapie Und Onkologie, 2021, 197, 558-559.	1.0	0
90	Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer $\hat{a} \in A$ systematic review. Senologie - Zeitschrift FÃ $\frac{1}{4}$ r Mammadiagnostik Und -therapie, 2018, 15, .	0.0	0

#	Article	IF	CITATIONS
91	Management of the axilla for high-risk early breast cancer (EBC) before and after neoadjuvant chemotherapy (NACT): an analysis of the multicentre GeparOcto trial. , 2020, 17, .		0
92	Wie empfinden und bewerten Patientinnen mit Mammakarzinom die einzelnen Therapiemodalit $\tilde{A}$ en: Ergebnisse einer Patientenbefragung im Rahmen der HYPOSIB - Studie (ARO 2013-05)., 2020, 17, .		0
93	Expert Discussion: Ductal Carcinoma in situ. Breast Care, 2021, 16, 1-4.	0.8	O
94	PrÃ <b>ĕ</b> perative Strahlentherapie (PRT) und Systemtherapie beim Mammakarzinom – welche Faktoren beeinflussen das Gesamtüberleben (OS)?. , 2020, 80, .		0
95	Pr $\tilde{A}$ perative Strahlentherapie beim Mammakarzinom mit Indikation f $\tilde{A}$ 1/4r eine neoadjuvante Chemotherapie-inwieweit wird durch die pr $\tilde{A}$ perative Radiotherapie die pCR-Rate beeinflusst?. , 2020, 80, .		0
96	Defective chondrogenic differentiation of murine embryonic stem cells treated with RGD-containing peptides. Journal of Stem Cells and Regenerative Medicine, 2010, 6, 59.	2.2	0